SwePub
Sök i LIBRIS databas

  Utökad sökning

WFRF:(Kumar Rajat)
 

Sökning: WFRF:(Kumar Rajat) > Interaction Between...

Interaction Between High-Dose Intravenous Busulfan and Post-Transplantation Cyclophosphamide on Hemorrhagic Cystitis After Allogeneic Hematopoietic Cell Transplantation

Carreira, Abel Santos (författare)
Univ Toronto, Dept Med, Sect Med Oncol & Hematol, Toronto, ON, Canada.;Univ Hlth Network, Princess Margaret Canc Ctr, Hans Messner Allogene Blood & Marrow Transplantat, Div Med Oncol & Hematol, Toronto, ON, Canada.
Salas, Maria Queralt (författare)
Univ Toronto, Dept Med, Sect Med Oncol & Hematol, Toronto, ON, Canada.;Univ Hlth Network, Princess Margaret Canc Ctr, Hans Messner Allogene Blood & Marrow Transplantat, Div Med Oncol & Hematol, Toronto, ON, Canada.;Hosp Clin Barcelona, Dept Hematol, Hematopoiet Cell Transplant Unit, IDIBAPS, Barcelona, Spain.
Remberger, Mats, Professor, 1955- (författare)
Uppsala universitet,Hematologi,Uppsala Univ Hosp, KFUE, Uppsala, Sweden.
visa fler...
Novitzky-Basso, Igor (författare)
Princess Margaret Hosp, Canc Ctr, Toronto, ON, Canada.
Law, Arjun Datt (författare)
Univ Toronto, Dept Med, Sect Med Oncol & Hematol, Toronto, ON, Canada.;Univ Hlth Network, Princess Margaret Canc Ctr, Hans Messner Allogene Blood & Marrow Transplantat, Div Med Oncol & Hematol, Toronto, ON, Canada.
Lam, Wilson (författare)
Univ Toronto, Dept Med, Sect Med Oncol & Hematol, Toronto, ON, Canada.;Univ Hlth Network, Princess Margaret Canc Ctr, Hans Messner Allogene Blood & Marrow Transplantat, Div Med Oncol & Hematol, Toronto, ON, Canada.
Pasic, Ivan (författare)
Univ Toronto, Dept Med, Sect Med Oncol & Hematol, Toronto, ON, Canada.;Univ Hlth Network, Princess Margaret Canc Ctr, Hans Messner Allogene Blood & Marrow Transplantat, Div Med Oncol & Hematol, Toronto, ON, Canada.
Mazzulli, Tony (författare)
Univ Toronto, Dept Lab Med & Pathobiol, Toronto, ON, Canada.;Sinai Hlth Syst, Dept Microbiol, Univ Hlth Network, Toronto, ON, Canada.
Cserti-Gazdewich, Christine (författare)
Univ Toronto, Dept Med, Sect Med Oncol & Hematol, Toronto, ON, Canada.;Univ Toronto, Dept Lab Med & Pathobiol, Toronto, ON, Canada.;Univ Hlth Network, Lab Med Program, Blood Transfus Lab, Toronto, ON, Canada.
Kim, Dennis (Dong Hwan) (författare)
Univ Toronto, Dept Med, Sect Med Oncol & Hematol, Toronto, ON, Canada.;Univ Hlth Network, Princess Margaret Canc Ctr, Hans Messner Allogene Blood & Marrow Transplantat, Div Med Oncol & Hematol, Toronto, ON, Canada.
Michelis, Fotios, V (författare)
Univ Toronto, Dept Med, Sect Med Oncol & Hematol, Toronto, ON, Canada.;Univ Hlth Network, Princess Margaret Canc Ctr, Hans Messner Allogene Blood & Marrow Transplantat, Div Med Oncol & Hematol, Toronto, ON, Canada.
Viswabandya, Auro (författare)
Univ Toronto, Dept Med, Sect Med Oncol & Hematol, Toronto, ON, Canada.;Univ Hlth Network, Princess Margaret Canc Ctr, Hans Messner Allogene Blood & Marrow Transplantat, Div Med Oncol & Hematol, Toronto, ON, Canada.
Gerbitz, Armin (författare)
Univ Toronto, Dept Med, Sect Med Oncol & Hematol, Toronto, ON, Canada.;Univ Hlth Network, Princess Margaret Canc Ctr, Hans Messner Allogene Blood & Marrow Transplantat, Div Med Oncol & Hematol, Toronto, ON, Canada.
Lipton, Jeffrey Howard (författare)
Univ Toronto, Dept Med, Sect Med Oncol & Hematol, Toronto, ON, Canada.;Univ Hlth Network, Princess Margaret Canc Ctr, Hans Messner Allogene Blood & Marrow Transplantat, Div Med Oncol & Hematol, Toronto, ON, Canada.
Kumar, Rajat (författare)
Univ Toronto, Dept Med, Sect Med Oncol & Hematol, Toronto, ON, Canada.;Univ Hlth Network, Princess Margaret Canc Ctr, Hans Messner Allogene Blood & Marrow Transplantat, Div Med Oncol & Hematol, Toronto, ON, Canada.
Hassan, Moustapha (författare)
Karolinska Institutet
Mattsson, Jonas (författare)
Univ Toronto, Dept Med, Sect Med Oncol & Hematol, Toronto, ON, Canada.;Univ Hlth Network, Princess Margaret Canc Ctr, Hans Messner Allogene Blood & Marrow Transplantat, Div Med Oncol & Hematol, Toronto, ON, Canada.;Univ Hlth Network, Princess Margaret Canc Ctr, Hans Messner Allogene Transplant Program, Div Med Oncol & Hematol, OPG Bldg,610 Univ Ave, Toronto, ON M5G 2M9, Canada.
visa färre...
Univ Toronto, Dept Med, Sect Med Oncol & Hematol, Toronto, ON, Canada;Univ Hlth Network, Princess Margaret Canc Ctr, Hans Messner Allogene Blood & Marrow Transplantat, Div Med Oncol & Hematol, Toronto, ON, Canada. Univ Toronto, Dept Med, Sect Med Oncol & Hematol, Toronto, ON, Canada.;Univ Hlth Network, Princess Margaret Canc Ctr, Hans Messner Allogene Blood & Marrow Transplantat, Div Med Oncol & Hematol, Toronto, ON, Canada.;Hosp Clin Barcelona, Dept Hematol, Hematopoiet Cell Transplant Unit, IDIBAPS, Barcelona, Spain. (creator_code:org_t)
Elsevier, 2023
2023
Engelska.
Ingår i: Transplantation and Cellular Therapy. - : Elsevier. - 2666-6375 .- 2666-6367. ; 29:9, s. 581.e1-581.e8
Relaterad länk:
https://urn.kb.se/re...
visa fler...
https://doi.org/10.1...
http://kipublication...
visa färre...
  • Tidskriftsartikel (refereegranskat)
Abstract Ämnesord
Stäng  
  • This study investigates the incidence and predictors of hemorrhagic cystitis (HC) in 960 adults undergoing allo- hematopoietic stem cell transplantation. Two hundred fifty-two (26.5%) patients received myeloablative conditioning regimens, and 81.4% received high-dose intravenous busulfan (HD Bu). Six hundred ninety-five (72.4%) patients received post-transplantation cyclophosphamide (PTCY)-based prophylaxis, and 91.4% additionally received anti-thymocyte globulin (ATG) and Cyclosporine A (CsA) (PTCY-ATG-CsA). Two hundred twenty-eight (23.8%) patients developed HC. The day 100 cumulative incidences of grades 2-4 and 3-4 HC were 11.1% and 4.9%. BK virus was isolated in 58.3% of urinary samples. Using HD BU myeloablative regimens increased the risk for grade 2-4 HC (hazard ratio [HR] = 1.97, P = .035), and HD BU combined with ATG-PTCY-CsA increased this 4 times (HR = 4.06, P < .001) for grade 2-4 HC compared to patients who received neither of these drugs. A significant correlation was documented between grade II-IV acute graft-versus-host disease and grade 2-4 HC (HR = 2.10, P < .001). Moreover, patients with BK-POS grade 2-4 HC had lower 1-year overall survival (HR = 1.51, P = .009) and higher non-relapse mortality (HR = 2.31, P < .001), and patients with BK-NEG grade 2-4 HC had comparable post-transplantation outcomes. In conclusion, intravenous HD Bu was identified as a predictor for grade 2-4 HC. Moreover, when HD Bu was combined with PTCY-ATG-CsA, the risk increased 4-fold. Based on the results provided by this study, preventing the onset of HC, especially in high-risk patients, is mandatory because its presence significantly increases the risk for mortality.

Ämnesord

MEDICIN OCH HÄLSOVETENSKAP  -- Klinisk medicin -- Hematologi (hsv//swe)
MEDICAL AND HEALTH SCIENCES  -- Clinical Medicine -- Hematology (hsv//eng)

Nyckelord

Hemorrhagic cystitis
PTCY
Busulfan
Allogeneic hematopoietic cell transplantation
Quality of care

Publikations- och innehållstyp

ref (ämneskategori)
art (ämneskategori)

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy